Aims-To produce a method to measure and quantify enzymatically active topoisomerase II in normal and neoplastic human cells. Methods-A crude cell lysate from density separated mononuclear cells from either peripherial blood or bone marrow was prepared as a source of topoisomerases. Using the lysate, minicircles from the Crithedia kinetoplast DNA complex were decatenated before being separated by agarose gel electrophoresis and visualised using ethidium bromide/ultraviolet fluorescence.
At presentation, most acute leukaemias show some response to treatment; however, with time most adult patients succumb to their disease due to relapse. Following relapse, treatment protocols become less effective and drug concentrations are escalated with the addition of other chemotherapeutic agents. This phenomenon of failing response to therapy with increased tumour load is often referred to collectively as the development of drug resistance.
There are many in vitro and in vivo models used to describe the development of drug resistance, including the multidrug resistance phenotype or MDR,' drug detoxification,' changes in both the level and structure of the drug target, 3 and changes in DNA repair mechanisms.4 All of these mechanisms may work alone or in concert to produce the phenotype in vivo of the eventual failure of response to treatment seen in patients with leukaemia. 6 The topoisomerases are a ubiquitous family of enzymes seen in bacteria (DNA gyrases) and in eukaryote organisms where two major forms exist: topoisomerase I which catalyse single strand DNA breaks and ligations; and topoisomerase II which catalyse the cleavage and ligation of double strand DNA breaks. These enzymes are believed to play important roles in DNA replication, repair and in gene transcription (for review see 7 8 Crithedia fasciculata (a gift of Dr I Hickson, Oxford) was grown in brain heart infusion medium (Difco) containing 10 ig/ml hemin, 100 gg/ml penicillin, 0.125 ,ug/ml streptomycin at 280C to 1-5 x 107/ml. DNA was prepared from the harvested protozoa (2 x 10") using standard lysis and chloroform/alcohol extraction methods. The mixture of genomic and kinetoplast DNA was treated with RNase A (bovine pancreas; Sigma, Poole, Dorset, UK) for 60 minutes at 37°C (50 jg/ml final concentration) and then mixed with molecular weight marker (5:3 ratio Hind III digested bacteriophage k markers; Integra Biosciences) to form the target DNA for the topoisomerase II assay. Adriamycin (pg/ml) 
